LAKE FOREST, CA – September 26, 2013 — Cryoport, Inc. (OTCBB: CYRX) and OCASA, Inc. have entered into a master services agreement to provide global cold chain logistics solutions for life science and biotech commodities requiring cryogenic temperatures. OCASA will have access to Cryoport’s full range of cryogenic business solution capabilities including its proprietary Cryoport Express® Shippers and cloud-based logistics management software platform, the CryoportalTM. Cryoport will leverage OCASA’s global logistics network to provide more complete global services to its customers. In conjunction with Cryoport and OCASA providing each other with logistics solutions, the Companies will engage in co-marketing, joint sales activities, and a wide range of customer-driven support requirements to provide comprehensive and seamless solutions to the life sciences and biotech industries.
Angel Guinea, Country Manager and Head of OCASA Logistics Solutions BioPharma Division stated, “This alignment allows us to leverage Cryoport’s proven cold chain solutions across our global logistics footprint, and we are enthusiastic about the mutual value that will result.”
Cryoport’s CEO Jerrell Shelton stated, "We are delighted that we have this new partnership with OCASA. It is centered around our ‘powered by cryoportSM’ strategy and makes all of our solutions available to OCASA. OCASA has a particularly strong presence in certain geographies of interest and has already been providing reliable logistics services to some of our customers on a global basis. With this expanded relationship we will accelerate sales into these markets and further broaden the awareness of our solutions in the biotechnology and life sciences industries.”
About OCASA Logistics Solutions
OCASA, Inc. is a global market leader in specialized international logistics with broad experience and specialization in the development of tailor-made logistics solutions. OCASA’s services include export, import/customs clearance, temperature controlled warehousing, secondary packaging and labeling, distribution, fulfillment, and general cold chain logistics for clinical trial investigational products, clinical trial samples/test kits, diagnostic specimens, commercial medications/vaccines, medical supplies/kits, controlled products, and dangerous infectious goods. For more information, visit www.ocasa.com.
About Cryoport, Inc.
Cryoport provides leading edge frozen shipping logistics solutions to the biotechnology and life science industries through the combination of purpose built proprietary hardware and software technologies and skilled total turnkey management of the entire logistics process. Cryoport Express® liquid nitrogen dry vapor shippers are validated to maintain a constant -150°C temperature for a 10 plus day dynamic shipment duration, and its Cryoportal™ Logistics Management Platform manages the entire shipment process, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. Cryoport’s total turnkey logistics solutions offer reliability, cost effectiveness, and convenience, while the use of recyclable and reusable components provides a “green” and environmentally friendly solution. Cryoport service options include recording the “chain of condition” and “chain of custody” for all shipments thereby meeting the exacting requirements for scientific work and for regulatory purposes. For more information visit www.cryoport.com.
Forward Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.